Evidence map›Paper›PMID 31821602›Full record

ArticleJournal of clinical laboratory analysis2020

LncRNA ANRIL/miR-125a axis exhibits potential as a biomarker for disease exacerbation, severity, and inflammation in bronchial asthma.

Shenglan Ye, Shan Zhu, Lijuan Feng

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Exosomal Long Non-Coding RNAs in Lung Diseases.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shenglan YeDepartment of Respiratory Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Shan ZhuDepartment of Respiratory Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lijuan FengDepartment of Emergency, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID https://orcid.org/0000-0002-9611-2132
Central Hospital of Wuhan · CN

Funding

Clinical Observation of Specific Immunotherapy Combined with Inhalation of Budesonide/Formoterol Aerosol in the Treatment of Respiratory Allergic Diseases WX17D06
6 · The paper itself

Abstract

backgroundThis study aimed to explore the correlation of lncRNA ANRIL/miR-125a axis with disease risk, severity, and inflammatory cytokines of bronchial asthma.

methodsPlasma samples from 90 patients with bronchial asthma at exacerbation (BA-E), 90 with bronchial asthma at remission (BA-R), and 90 controls (healthy subjects) were collected. The qPCR was used for lncRNA ANRIL and miR-125a detection, and ELISA was adopted for pro-inflammatory cytokines detection. Participants' characteristics, laboratory tests, and the pulmonary ventilation function examinations were recorded.

resultsLncRNA ANRIL was negatively correlated with miR-125a in BA-E patients, BA-R patients, and controls. LncRNA ANRIL/miR-125a axis was upregulated in BA-E patients compared with BA-R patients and controls. ROC curve analyses illuminated that lncRNA ANRIL/miR-125a axis was of good value in distinguishing BA-E patients from BA-R patients and controls. As to pulmonary ventilation functions, lncRNA ANRIL/miR-125a axis was negatively associated with FEV

conclusionLncRNA ANRIL/miR-125a is potentially indicative of disease exacerbation, exacerbation severity, and inflammation for bronchial asthma, while these findings are preliminary and need further confirmation.

Indexed as

Disease ProgressionSeverity of Illness IndexAdultAsthmaBiomarkersCase-Control StudiesCytokinesFemaleGene Expression RegulationHumansInflammationInflammation MediatorsMaleMicroRNAsPulmonary VentilationRemission InductionBiomarkersCDKN2B antisense RNA, humanCytokinesInflammation MediatorsMicroRNAsMIRN125 microRNA, humanRNA, Long Noncodingbronchial asthmadisease riskexacerbationinflammatory cytokinesLncRNA ANRIL/miR-125a axis

Identifiers

PMID31821602
PMCPMC7083478
OpenAlexW2994886544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.